안트로젠

065660KOSDAQ

45.0 / 100

Reference Date: 2026-09-08

Financial Score19.5 / 40

News Sentiment12.5 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 9.4% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Antrogen is a biotech company specializing in the development and production of stem cell-based therapeutics, having commercialized the world's first adipose-derived stem cell treatment for Crohn's disease fistulas, 'Cupistem,' in 2012. It also holds exclusive distribution rights for pulmonary hypertension treatments 'Remodulin' and 'Tyvaso' in South Korea, while expanding its pipeline for tissue-engineered therapies and treatments for rare/incurable diseases.

Number of Employees

32people

Average Salary

34.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

1.76Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE

-1.39Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

0.22Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲7.7% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲30.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -1.9% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (1%, downtrend)

Current 15,340Won52-week high 58,00052-week low 14,840

1-month return1.0Point

1m -9.39% (falling)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-14